SCHEMBL3127049

SCHEMBL3127049

CC(C)(C)OC(=O)N(CCO)Cc1cccc([N+](=O)[O-])c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
LMNA P02545 3/20 0.56
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
PYCR1 P32322 1/20 0.44
MAPT P10636 4/20 0.44
ACHE P22303 1/20 0.43
SSTR4 P31391 1/20 0.43
SLC2A1 P11166 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ALOX5 P09917 1/20 0.42
MAOB P27338 2/20 0.42
MAOA P21397 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30877118 0.93 ALDH1A1 (0.51) ALDH1A1LMNACYP1A2CYP2D6CYP2C9
SCHEMBL30877102 0.92 ALDH1A1 (0.50) ALDH1A1LMNACYP1A2CYP2D6CYP2C9
SCHEMBL15498167 0.91 CYP1A2 (0.49) ALDH1A1LMNACYP1A2CYP2D6CYP2C9
SCHEMBL18994885 0.90 ALDH1A1 (0.46) ALDH1A1LMNACYP1A2CYP2D6CYP2C9
SCHEMBL9900623 0.89 ALDH1A1 (0.51) ALDH1A1LMNACYP1A2CYP2D6CYP2C9
SCHEMBL16468408 0.89 ALDH1A1 (0.51) ALDH1A1LMNACYP1A2CYP2D6CYP2C9
SCHEMBL6674347 0.88 CYP1A2 (0.54) ALDH1A1LMNACYP1A2CYP2D6CYP2C9
SCHEMBL16467912 0.88 ALDH1A1 (0.50) ALDH1A1LMNACYP1A2CYP2D6CYP2C9
SCHEMBL16467923 0.87 LMNA (0.50) ALDH1A1LMNACYP1A2CYP2D6CYP2C9
SCHEMBL30877910 0.87 ALDH1A1 (0.44) ALDH1A1LMNACYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2143714-B1 TETRAHYDROISOQUINOLINE COMPOUND KOWA CO (JP) 2013-06-05 EP disclosed
US-8273766-B2 Tetrahydroisoquinoline compound KOWA COMPANY, LTD. (JP) 2012-09-25 US disclosed
US-8273766-B2 Tetrahydroisoquinoline compound KOWA COMPANY, LTD. (JP) 2012-09-25 US disclosed
US-8273766-B2 Tetrahydroisoquinoline compound KOWA COMPANY, LTD. (JP) 2012-09-25 US disclosed
US-20100120844-A1 TETRAHYDROISOQUINOLINE COMPOUND KOWA COMPANY, LTD. (JP) 2010-05-13 US disclosed
US-20100120844-A1 TETRAHYDROISOQUINOLINE COMPOUND KOWA COMPANY, LTD. (JP) 2010-05-13 US disclosed
US-20100120844-A1 TETRAHYDROISOQUINOLINE COMPOUND KOWA COMPANY, LTD. (JP) 2010-05-13 US disclosed
EP-2143714-A1 TETRAHYDROISOQUINOLINE COMPOUND Kowa Company, Ltd. (JP) 2010-01-13 EP disclosed
EP-2143714-A1 TETRAHYDROISOQUINOLINE COMPOUND Kowa Company, Ltd. (JP) 2010-01-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120844-A1 TETRAHYDROISOQUINOLINE COMPOUND CCR3, CCR5, CCR1 ALDH1A1 2938/4885LMNA 3837/4885CYP1A2 2092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.